logo
  • 首页
  • 学术期刊
  • 论文检测
  • AIGC检测
  • 热点
  • 更多
    • 数据

Ipilimumab/nivolumab/nivolumab/pembrolizumabType 1 diabetes: case report

被引:0
|
作者:
机构:
来源:
Reactions Weekly | 2023年 / 1956卷 / 1期
关键词:
D O I:
10.1007/s40278-023-38899-3
中图分类号:
学科分类号:
摘要:
引用
收藏
页码:286 / 286
相关论文
共 50 条
  • [21] Ipilimumab/nivolumab/methylprednisoloneVarious toxicities: case report
    Reactions Weekly, 2022, 1896 (1) : 255 - 255
  • [22] Ipilimumab/nivolumab/pembrolizumabInterstitial nephritis: case report
    Reactions Weekly, 2019, 1763 (1) : 204 - 204
  • [23] Ipilimumab/nivolumab/vorinostatVarious toxicities: case report
    Reactions Weekly, 2025, 2047 (1) : 223 - 223
  • [24] Ipilimumab/nivolumab/relatlimabColitis and pancreatitis: case report
    Reactions Weekly, 2020, 1803 (1) : 146 - 146
  • [25] Ipilimumab/nivolumab/pembrolizumabVarious toxicities: case report
    Reactions Weekly, 2022, 1894 (1) : 193 - 193
  • [26] Ipilimumab/nivolumab/tozinameranVarious toxicities: case report
    Reactions Weekly, 2022, 1906 (1) : 231 - 231
  • [27] Ipilimumab/nivolumab/sunitinibVarious toxicities: case report
    Reactions Weekly, 2023, 1938 (1) : 767 - 767
  • [28] Ipilimumab/nivolumab/sunitinibVarious toxicities: case report
    Reactions Weekly, 2022, 1913 (1) : 267 - 267
  • [29] Ipilimumab/ nivolumab/ pembrolizumabMultiple toxicities: case report
    Reactions Weekly, 2016, 1606 (1) : 92 - 92
  • [30] Ipilimumab/nivolumab/pembrolizumabLack of efficacy: case report
    Reactions Weekly, 2025, 2041 (1) : 200 - 200
← 12345 →